Artificial intelligence assisted home therapy settings for dialysis

Information

  • Patent Grant
  • 12154673
  • Patent Number
    12,154,673
  • Date Filed
    Monday, August 2, 2021
    3 years ago
  • Date Issued
    Tuesday, November 26, 2024
    4 days ago
Abstract
A medical device is provided, including: a therapeutic subsystem to deliver a medical therapy, including a sensor to monitor a biometric health factor; a user interface; a controller, including a processor and a memory; therapy software including instructions encoded within the memory to instruct the processor to receive a prescribed therapy, to receive a therapeutic setting recommendation, and to display the therapeutic setting recommendation to an operator via the user interface; a network interface, and instructions to receive, via the network interface, a prepared artificial intelligence (AI) model from a cloud service; and an AI circuit having execution hardware including at least one logic gate, and further including instructions to instruct the execution hardware to execute the prepared AI model to provide a recommended therapy setting for the therapeutic subsystem, wherein the circuit is further to incorporate into the prepared AI model data from the sensor.
Description
FIELD

Devices, systems, and methods are provided for providing artificial intelligence assisted home therapy settings for a medical apparatus. The devices, system, and methods are related to, though not exclusively, to a system and method of providing artificial intelligence assisted home therapy settings for dialysis.


BACKGROUND

Biomedical devices and other therapeutic apparatus improve human lives by providing therapeutic treatment, which may for example treat diseases or otherwise improve the functioning of the human body. Certain biomedical devices are entering home use but can require relatively complex or specific control settings. The control settings are needed for proper function and usefulness of a medical treatment such as for hemodialysis. For example, in-center hemodialysis is often administered and monitored by trained, in-center clinicians. However, a nephrologist may prescribe home treatment of hemodialysis to remove toxins such as urea from the blood. In setting up home hemodialysis, the patient and a primary care partner can be trained to perform dialysis safely, and to handle problems in the event of adverse conditions during the session. The in-center training might take several weeks to several months. Apart from training, the patient and caretaker can be provided with material relevant to the medication, safety measures, proper usage, sanitation, installation, and access to 24-hour support from care centers. However, the resulting cognitive load on the patient and caretaker can be large. Even after many hours of training, some patients and caretakers may be unable to properly comprehend and adjust control settings as may be required. Moreover, even trained clinicians in a clinical environment may be overwhelmed or fail to implement or recognize a problem. These issues could result in inconsistencies or sub-optimal outcomes in the dialysis adequacy and may pose health and safety risks to the patient.


The known systems and methods fail to provide a suitable home therapy system that assists and/or automates the process of setting control parameters. The known systems and methods fail to ameliorate a steep learning curve and cognitive load on home therapy systems and methods imposed upon caregivers and patients receiving home dialysis. The known systems and methods fail to suggest and/or automate treatment parameters such as the blood flow rate/profiles with visual representation rates during hemodialysis delivery and blood return for home therapy.


Hence, there is a need for an electronic system that can advise patients during in-home treatments. There is a need for systems and methods that can automate or provide recommendations that can be implemented by a user whether in a clinical or home setting. There is a related need to provide analysis of patient records and other historical data to assist in setting parameters for a therapy. There is a further need for systems and methods for providing recommendations for blood flow rate and similar treatment parameters influencing a medical therapy such as dialysis. There is a need for a machine implemented system and method for recommending and/or setting parameters used in dialysis. There is a need for a system and method suitable for dialysis home therapy. There is a related need for recommending and automating a blood flow rate using a therapy or smart engine with artificial intelligence. The need relates to assisting patients, caregivers, clinicians, and doctors administering treatment themselves in a home or clinical setting. The need includes aiding medical professionals who are experienced, but who can benefit from the insights of a machine learning system and method. The need extends a network connected medical device that receive and send data. The need still further includes a medical device that can receive and send algorithms, recommendations, or instructions of any type.


SUMMARY OF THE INVENTION

The systems and methods can help reduce a steep learning curve and cognitive load of performing therapy whether in a clinical or home setting by any type of user. The system and method disclosed herein can help both nurses and patients who are participating in-home dialysis, and also can help physicians and others in-clinic who are desirous of electronic assistance in sorting through the large volume of records available.


The first aspect relates to a medical device. In any embodiment, the medical device can include: a therapeutic subsystem to deliver a medical therapy, including one or more sensors to monitor a biometric health factor; a user interface; a controller, including a processor and a memory; therapy software including instructions encoded within the memory to instruct the processor to receive a prescribed therapy, to receive a therapeutic setting recommendation, and to display the therapeutic setting recommendation to an operator via the user interface; a network interface, and instructions to receive, via the network interface, a prepared artificial intelligence (AI) model from a cloud service; and an AI circuit having execution hardware including at least one logic gate, and further including instructions to instruct the execution hardware to execute the prepared AI model to recommend a therapy setting for the therapeutic subsystem, wherein the circuit is incorporated into the prepared AI model data from the sensor.


In any embodiment, the execution hardware can include the processor.


In any embodiment, the device can be selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.


In any embodiment, the device can be a dialysis machine.


In any embodiment, the prepared AI model can incorporate input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.


In any embodiment, the therapy setting recommendation can include a blood flow rate recommendation.


In any embodiment, the therapy software instructions can further automatically select a recommended blood flow rate.


In any embodiment, the therapy software instructions can further detect a changed blood flow rate during therapy, and the AI circuit can further predict a recommendation according to the changed blood flow rate.


In any embodiment, the sensor can detect an adverse condition, and the AI circuit can recommend a blood flow rate according to the adverse condition.


In any embodiment, the adverse condition can include low patient blood pressure.


In any embodiment, the therapy software instructions can further save one or more blood flow rate profiles for a patient.


In any embodiment, the therapeutic setting recommendation can be selected from blood flow rate, sodium profile, and ultrafiltration rate profile.


In any embodiment, the user interface can include a control to request a therapeutic setting recommendation.


In any embodiment, the user interface can include one or more controls to automatically accept or reject recommended therapeutic settings.


In any embodiment, the therapy software instructions can further download the treatment parameters from a cloud service.


In any embodiment, the AI circuit can provide a high clearance prediction.


In any embodiment, the AI circuit can further concurrently provide a plurality of recommended therapeutic settings.


In any embodiment, the AI circuit can provide an AI model selected from the group consisting of linear regression, logistic regression, linear discriminant analysis, decision tree, naïve Bayes, k-nearest neighbors, learning vector quantization, support vector machine, random forest, neural network, convolutional neural network, and deep neural network.


In any embodiment, a system can be provided, including the medical device of any previous embodiment, and further including a cloud service, the cloud service including a hardware platform including a processor and a memory, and instructions encoded within the memory to instruct the processor to receive a plurality of historical patient inputs and build the prepared model from the plurality of historical patient inputs.


In any embodiment, a system can be provided, wherein the prepared model can be a patient-specific model.


In any embodiment, a system can be provided, wherein the prepared model can be specific to a class of patients.


The features disclosed as being part of the first aspect can be in the first aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the first aspect can be in a second or third aspect described below, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.


The second aspect relates to a method of providing therapy recommendations for a medical device. In any embodiment, the method can include: receiving a prescribed therapy regimen for a patient; receiving a patient profile for the patient; operating an artificial neural network (ANN) to compute a recommended therapy setting according to a regression model, wherein the prescribed therapy regimen and the patient profile are inputs to the regression model; and displaying the recommended therapy in a human-readable format.


In any embodiment, the method can further include executing on hardware that includes a processor.


In any embodiment, the device can be selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.


In any embodiment, the device can be a dialysis machine.


In any embodiment, the ANN can receive an input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.


In any embodiment, the recommended therapy setting can include a blood flow rate recommendation.


In any embodiment, the method can further include automatically selecting a recommended blood flow rate.


In any embodiment, the method can further include detecting a changed blood flow rate during therapy, and the ANN can further predict a recommendation according to the changed blood flow rate.


In any embodiment, the method can further include detecting an adverse condition, and the ANN can recommend a blood flow rate according to the adverse condition.


In any embodiment, the adverse condition can include low patient blood pressure.


In any embodiment, the method can further include saving one or more blood flow rate profiles for a patient.


In any embodiment, the method can further include selecting the recommended therapy setting from blood flow rate, sodium profile, and ultrafiltration rate profile.


In any embodiment, the method can further include requesting a therapeutic setting recommendation.


In any embodiment, the method can further include automatically accepting or rejecting recommended therapeutic settings.


In any embodiment, the method can further include downloading the historical treatment parameters from a cloud service.


In any embodiment, the ANN can provide a high clearance prediction.


In any embodiment, the ANN can further concurrently provide a plurality of recommended therapeutic settings.


The features disclosed as being part of the second aspect can be in the second aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the second aspect can be in the first or third aspect described below, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.


The third aspect relates to one or more tangible, non-transitory computer-readable media. In any embodiment, the computer-readable media can have stored thereon executable instructions to: receive a therapy prescription for a patient; receive a patient profile for the patient; run, in an ANN, a regression model having as inputs the therapy prescription and the patient profile, and as an output a recommended therapy setting for a medical device; and operate a user interface to display the recommended therapy setting.


In any embodiment, the instructions can be to run on hardware including a processor.


In any embodiment, the instructions can be to operate a device selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.


In any embodiment, the instructions can be to operate a dialysis machine.


In any embodiment, the ANN can receive an input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.


In any embodiment, the recommended therapy setting can include a blood flow rate recommendation.


In any embodiment, the instructions can automatically select a recommended blood flow rate.


In any embodiment, the instructions can be to further detect a changed blood flow rate during therapy, and the ANN can further predict a recommendation according to the changed blood flow rate.


In any embodiment, the instructions can be to further detect an adverse condition, and the ANN can recommend a blood flow rate according to the adverse condition.


In any embodiment, the adverse condition can include low patient blood pressure.


In any embodiment, the instructions can be to further save one or more blood flow rate profiles for a patient.


In any embodiment, the recommended therapy setting can be selected from blood flow rate, sodium profile, and ultrafiltration rate profile.


In any embodiment, the user interface can include a control to request a therapeutic setting recommendation.


In any embodiment, the user interface can include one or more controls to automatically accept or reject recommended therapeutic settings.


In any embodiment, the instructions can be further to download the historical treatment parameters from a cloud service.


In any embodiment, the ANN can provide a high clearance prediction.


In any embodiment, the ANN can further concurrently provide a plurality of recommended therapeutic settings.


The features disclosed as being part of the third aspect can be in the third aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements. Similarly, any features disclosed as being part of the third aspect can be in the first or second aspect, either alone or in combination, or follow any arrangement or permutation of any one or more of the described elements.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a system-level view of a medical device ecosystem.



FIG. 2 is a system-level diagram of a medical treatment ecosystem.



FIG. 3 is a block diagram of a medical device.



FIGS. 4 and 5 illustrate example outputs that can be provided on a user interface.



FIG. 6 is a block diagram illustrating interaction between a cloud service and a medical device.



FIG. 7 is a flowchart of a method.



FIG. 8 is a flowchart of an additional method.



FIG. 9 is a block diagram of a network function virtualization (NFV) infrastructure.





DETAILED DESCRIPTION

Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art.


The articles “a” and “an” are used to refer to one to over one (i.e., to at least one) of the grammatical object of the article. For example, “an element” means one element or over one element.


The term “biomedical device” refers to any device that provides therapy, monitoring, or telemetry for a biological entity, and most particularly, for a human. Biomedical devices can passively monitor a human patient, or they can actively administer a therapeutic service.


The term “biometric s” can be any measurement obtained from a living organism. In general, the measurement is indicative of a health status of the living organism such as analytical data obtained from various lab testing and history data or from any sensor that can sense a measurand of any type, e.g., blood pressure, body weight, temperature, etc. One of ordinary skill will appreciate that many biometric parameters can be indicated of a health status and are all contemplated.


The term “blood flow rate” refers to the rate at which blood is extracted and filtered during hemodialysis.


The term “blood flow rate profile” refers to a time series profile that defines blood flow rates at different points of therapy.


The term “blood pressure” refers to a measure of the systolic and diastolic blood pressure.


The term “circuit” refers to any electronic analog, digital, or mixed-signal electronic network. In the case of digital or mixed-signal networks, the circuit can also include instructions or other inputs that are used to program the circuit.


The term “cloud service” refers to any collection of one or more machines, connected via a network such as the internet, that provides a non-local service.


The term “continuous positive airway pressure machine” refers to a medical device that provides forced air to a patient while sleeping to mitigate sleep apnea.


The term “controller” refers to a programmable circuit, which can include instructions to program the circuit, that controls a device.


The term “convolutional neural network” refers to a form of neural network that uses mathematical convolution to define the relationship between neurons.


The term “decision tree” refers to a branching model, with yes/no (or similar) decisions at each branch.


The term “deep neural network” refers to a neural network that generally includes an input layer, one or more intermediate hidden layers, and an output layer, in which each neuron of each layer is linked to each neuron of the next layer.


The term “dialysis machine” refers to a medical device that provides in-home or in-clinic hemodialysis.


The term “dialyzer permeability” refers to the permeability of a hollow fiber dialyzer bundle.


The term “dialyzer type” refers to one of several types of dialyzers, such as coil, parallel plate, hollow fiber, or ultrafiltration.


The term “execution hardware” refers to programmable hardware to read and act on the instructions of a computer program.


The term “external neural stimulator” refers to an electrical device to stimulate neurons.


The term “high clearance prediction” refers to a predicted condition to provide high dialysis clearance.


The term “human-readable format” refers to any format that is readily perceptible and understandable by a human.


The term “instructions” refers to machine-readable data that cause a processor to execute an algorithm. In the case of a microprocessor or microcontroller, the instructions can be a series of operation codes that, in a particular sequence, cause the processor to execute a desired algorithm. In the case of a field-programmable gate array (FPGA) or application-specific integrated circuit (ASIC), the instructions can be written in a hardware description language that is used to configure the circuit to carry out the algorithm.


The term “insulin pump” refers to a medical device that injects insulin into a patient.


The term “interface” refers to any combination of hardware, software, and/or firmware that enables one object to communicatively couple to another object.


The term “intravenous fluid device” refers to a device that injects fluid into a vein.


The term “k-nearest neighbors” refers to a model that makes predictions by mapping an input data set into an n-dimensional space, and identifying, for each node of interest, the k nodes that are nearest to a point in the space.


The term “learning vector quantization” refers to an evolution of k-nearest neighbors that employs a neural network.


The term “linear discriminant analysis” refers to a subclass of logistic regression that can be used when two or more classes can exist in the output.


The term “linear regression” refers to a statistical model that fits data to a line.


The term “logic gate” refers to an electronic circuit that receives one or more logical inputs, and provides at least one logical output as a function such as AND, OR, XOR, NAND, NOR, XNOR, delay, unity, or selection.


The term “logistic regression” refers to a statistical model that fits data to a logarithm, and is able to predict binary results.


The term “medical device” refers to an electronic device that provides at least one medical function.


The term “memory” refers to any electronic medium capable of storing encoded data.


The term “naïve Bayes” refers to a model that can predict a conditional probability according to a Bayesian calculation.


The term “neural network” refers to a form of artificial intelligence, not limited to a single algorithm, in which artificial “neurons” are connected in a network.


The term “operator” refers to a human who operates a device.


The term “patient access type” refers to the type of access to the patient, commonly one of fistula, graft, or catheter.


The term “patient condition” refers to any measure of patient health or status.


The term “patient profile” refers to a profile of blood flow rate across time, specific to a patient.


The term “processor” refers to any programmable or configurable logic circuit, which can be configured to execute a desired algorithm. A processor can provide a generalized instruction set, such as in the case of a microprocessor or microcontroller or can be configured in hardware as in the case of an application-specific integrated circuit (FPGA). In some cases, processors can be emulated and/or virtualized. For example, virtualization technology can provide a virtual processor running under a hypervisor, or other kind of virtualization layer, in which case the “processor” can include the emulation layer, as well as the physical processor that ultimately executes the instructions.


The term “random decision forest” refers to a form of decision tree, where multiple samples are processed by decision trees, and the results are aggregated.


The term “sodium profile” refers to the sodium concentration of dialysis fluid.


The term “software” refers to any sequence of instructions to instruct a programmable hardware to carry out an algorithm.


The term “support vector machine” refers to a model that employs a hyperplane line that separates data input nodes with different values.


The term “therapeutic subsystem” refers to a portion of a medical apparatus that administers therapy or treatment to a patient.


The term “therapy” refers to a medical procedure or regimen delivered to a patient.


The term “therapy method” refers to the method by which a therapy is delivered to the patient.


The term “therapy regimen” refers to the prescribed parameters, length, and methods of a treatment.


The term “therapy software” refers to software that controls administration and/or monitoring of therapy.


The term “ultrafiltration” refers to a form of hemodialysis in which excess fluid, such as water, is removed from the blood (in addition to removing toxins).


The term “ultrafiltration rate profile” refers to a profile, over time, of the rate at which ultrafiltration is performed during hemodialysis.


Medical Device Ecosystem



FIG. 1 is a system-level view of a medical device ecosystem 100. Ecosystem 100 includes a home health network, wherein a treatment such as dialysis can be administered by patient 104, or by a caregiver for patient 104. The patient 104 can be connected to an immediate or easy access to a healthcare professional to monitor or adjust certain treatment parameters. The term “biometric health factor” can be any measurement obtained from a living organism. In general, the measurement is indicative of a health status of the living organism such as analytical data obtained from various lab testing and history data of treatment parameters such as patient access type, dialyzer type, therapy method, patient conditions, fluid removal, dialyzer permeability, patient's weight, dry weight, treatment time, treatment goal, and other physiological or appropriate clinical parameters to identify and recommend the optimal blood flow rate for a patient at each phase of hemodialysis treatment delivery.


Patient 104 operates hemodialysis machine 108, which includes a graphical user interface (GUI) 112. GUI 112 permits patient 104 to interact with hemodialysis machine 108, and to provide inputs and view outputs. For example, GUI 112 can include a flow rate profile display, which could optionally include flow rate points. In some cases, GUI 112 can include a touch-sensitive display, so that patient 104 can directly interact with GUI 112, via the display.


Hemodialysis machine 108 can include various sensors that provide feedback to monitor the success and safety of the dialysis operation. For example, a real-time blood pressure monitoring circuit (RT BP Mon.) 114 can be provided, so that the patient's blood pressure can be monitored in real-time, or near real-time, and so that the system can detect whether the patient's blood pressure drops dangerously low.


Ecosystem 100 can also include a home gateway 120, which connects to various devices that can help provide useful inputs to hemodialysis machine 108. For example, a smart scale 116 could be used to measure the patient's dry weight, and/or the patient's weight after dialysis. Home blood pressure monitor 118 could be used to periodically check the blood pressure of patient 104, and to keep track of blood pressure trends. In some illustrative embodiments, hemodialysis machine 108, smart scale 116, and/or home blood pressure monitor 118 can communicatively couple to home gateway 120, such as via a wired or wireless network. Home gateway 120 can act as a gateway between the home environment and internet 124, which provides a wider and uncontrolled network.


The home gateway 120 can provide for communication between the home gateway 120 and a cloud data service 132. The cloud data service 132 can have various software modules to connect to the home gateway 120. Notably, the cloud data service 132 can establish a data communication channel with the home gateway 120 through a TCP/IP protocol or other suitable process, where a terminal is connected to the home gateway 120. The home gateway 120 software can send a first software message to the cloud data service 132 through the data communication channel so that the home gateway 120 establishes connection with cloud data service 132. One of ordinary will understand that other suitable connection methods, steps, and protocols can be implemented to establish such connection with an external cloud server. The cloud data service 132 can communicatively couple to home gateway 120 via internet 124 and can provide services to patient 104. For example, cloud data service 132 can provide a pre-trained AI model to hemodialysis machine 108, which can enable an artificial intelligence circuit on hemodialysis machine 108 to provide treatment parameter suggestions, such as a suggested flow rate or a flow rate profile. In some cases, clinic 128 can also connect to cloud data service 132 via internet 124, or via an intranet or other internal network. Clinic 128 can provide data such as electronic health records, a treatment prescription, and other inputs as described herein to cloud data service 132. Cloud data service 132 can then use those data to build the pre-trained AI model for use by hemodialysis machine 108. In some cases, the pre-trained AI model can be specific to patient 104, rather than a general model that can be used by many patients. In other embodiments, a general model that is applicable to a class or group of patients could also be provided.


Medical Treatment Ecosystem



FIG. 2 is a system-level diagram of a medical treatment ecosystem 200. Whereas medical device ecosystem 100 of FIG. 1 takes place in a home treatment context, ecosystem 200 can take place in a clinical setting. Thus, patient 204 can be assisted by a healthcare professional 210, who can be, for example, a registered nurse trained in the use of hemodialysis machine 209, or can be or include a nephrologist, or other healthcare professional. Healthcare professional 210 may, as a general rule, have greater training than patient 204, if patient 204 were required to operate hemodialysis machine 209 individually. However, healthcare professional 210 can still benefit from recommendations, such as a recommended blood flow rate or blood flow rate profile.


In this example, within the clinic there is an enterprise gateway 220, which provides connectivity between various devices. Similar to FIG. 1, enterprise gateway 220 connects either via an intranet or via the internet to cloud data service 240. Enterprise gateway 220 can also provide connections to a lab terminal 236 and a doctor terminal 238. A physician can use doctor terminal 238 to input parameters, such as a treatment prescription and other recommendations. Lab terminal 236 can provide lab results, as well as access to electronic health record (EHR) and other data. Cloud data service 240 can be configured to collect various inputs, and to build a pre-trained AI model that can be run on hemodialysis machine 209. Other inputs can be collected via smart devices around the clinic, such as a smart scale 224, a blood pressure kit 228, and a pulse oximeter 232, by way of illustrative and nonlimiting example. As before, these devices, along with hemodialysis machine 209, can communicatively couple to enterprise gateway 220 via a wired or wireless network. Thus, while healthcare professional 210 is administering treatment to patient 204 via hemodialysis machine 209, she can operate GUI 212 to select treatment options, including a blood flow rate. She can also have access to a button, such as a “quick assist” button, that provides the ability to request a recommendation for a blood flow rate, according to current treatment parameters. As before, a real-time or near real-time blood pressure monitoring circuit 214 can be provided on hemodialysis machine 209 and can monitor patient 204 to ensure that his blood pressure does not drop below a danger threshold.


Medical Device



FIG. 3 is a block diagram of a medical device 300. Medical device 300 can be, for example, a hemodialysis machine, or any other suitable medical device. Furthermore, medical device 300 could also stand for a class of devices that could benefit from the teachings of the present specification, including devices that are not medical devices.


Medical device 300 includes a user interface 304, a therapeutic subsystem 308, a hardware platform 312, therapy software 316, an AI engine 320, and a recommendation engine 324. These are provided by way of illustrative and nonlimiting example. One of ordinary will understand that not all elements need be present in each embodiment, and some embodiments can include other elements. Furthermore, while these elements are shown as separate blocks, this does not necessarily imply that they are required to be provided as physically separate devices, or on separate hardware. The recommendation engine 324 can be provided may be a server, cloud service, or the like.


User interface 304 can include, for example, a touchscreen display, and can provide input options for configuring therapy. User interface 304 can also provide, for example, a graphical display of a blood flow rate or blood flow rate profile, as illustrated below in FIGS. 4 and 5.


Therapeutic subsystem 308 includes the hardware and software for providing the actual therapy. For example, therapeutic subsystem 308 can provide the pumps, filters, chemicals, pharmaceutical compounds, or other objects that are used to provide the therapy to the patient.


Hardware platform 312 can include the hardware for operating medical device 300. This could include, for example, a microcontroller, volatile and/or nonvolatile memory, interfaces, and other hardware elements. Hardware platform 312 can drive user interface 304, can control or interface with therapeutic subsystem 308, and can provide the platform for therapy software 316, AI engine 320, and recommendation engine 324.


Therapy software 316 can include software that interfaces with therapeutic subsystem 308 to provide therapy, to interface with sensors and other inputs, to collect user inputs via user interface 304, and to process results.


AI engine 320 includes an AI circuit which can be programmed to provide an artificial intelligence model. For example, AI engine 320 could include an ANN, a decision tree, or any other artificial intelligence engine or algorithm. By way of illustrative and nonlimiting example, AI engine 320 can provide an algorithm selected from a group including linear regression, logistic regression, linear discriminant analysis, decision tree, naïve Bayes, k-nearest neighbors, learning vector quantization, support vector machine, random forest, or deep neural network.


AI engine 320 may, in some examples, be a relatively limited AI circuit, and cannot provide all of the training or preprocessing that a full AI solution requires. Rather, AI engine 320 can receive a preprocessed or pre-trained model from an outside source, such as a cloud service, and can run that model based on localized inputs within medical device 300. Thus, much of the preprocessing can be provided in the cloud, where greater processing resources can be available. AI engine 320 can therefore be a relatively lightweight AI engine, and can perform only the processing necessary to make decisions in real-time, or near real-time, on medical device 300.


Recommendation engine 324 interfaces with user interface 304 and AI engine 320. Recommendation engine 324 can receive, via user interface 304, a request for a recommendation, such as when the user operates a quick assist button, or some other function. Recommendation engine 324 can also receive from AI engine 320 a recommendation, such as a recommended blood flow rate or blood flow rate profile. This can be provided to the user via user interface 304, and, in some embodiments, the user can be able to either accept or reject the recommendation.


Blood pressure monitoring sensor 330 can be used to monitor the patient's blood pressure in real-time, or near real-time, and to optionally compare that blood pressure to a threshold, to determine whether the patient's blood pressure is below a threshold with a safety margin, and/or below a danger threshold.


Thus, while there is an adequate knowledge base of individuals who understand hemodialysis therapy, and who have the experience to appropriately adjust parameters during sessions, the application and transition of this acquired knowledge can be a challenge. During in-center sessions, if there is a need to change programming parameters, an in-house nephrologist or experienced home therapy nurse can be consulted. But for the in-home care setting, the patient or caretaker may not even realize that a particular parameter requires a need to consult a professional. Thus, although 24-hour service support is available to put the patient in contact with a home therapy registered nurse (RN) or nephrologist, the patient may not even realize when these services are needed. Furthermore, even when the patient does realize that a consultation is required, the consultation can take a long time, requiring the patient to contact the 24-hour service, explain the issue, get potential solutions, and walk through the results.


Furthermore, for a nephrologist or RN to provide appropriate consultation, the professional may need to skim through the history of medical practice and EHRs for the patient to provide a prescription that is targeted to the patient's individual circumstances. The prescription may vary based on the experience level of the professional, as the professional may lack a generic tool to view treatment parameter recommendations.


Embodiments of this specification achieve benefits by suggesting and/or automating treatment parameters such as blood flow rate and profiles, and can optionally provide a visual representation of the blood flow rate during hemodialysis. This can be observed by both patients and attending nurses during hemodialysis delivery and blood return.


For many individuals, the effectiveness of dialysis treatment is dependent on the blood flow. Thus, the present specification uses a blood flow rate recommendation for dialysis treatment as an illustrative example of the principles taught herein. One of skill will understand that the dialysis machines disclosed herein could be replaced by any other biomedical device, or by any other device that could benefit from the teachings of this specification. Furthermore, blood flow rate could be replaced by any other treatment parameter that influences dialysis clearance, or by some other therapeutic factor for dialysis, or a different therapy. Furthermore, examples of the present specification are disclosed in terms of hemodialysis home therapy methods that are performed by patients or attended by registered nurses in the home. However, the teachings of this specification can also benefit physicians or other professionals who desire an aid for their own analysis. Embodiments disclosed herein recommend and automate blood flow rate using a therapy or smart engine with an AI assistance.


In one illustrative example, a cloud-based analysis module performs initial analysis on a number of parameters, and then provides a pre-trained AI model that can be deployed on an individual system. This pre-trained model can then be distributed, for example, via a secure network connection to an individual device that is performing in-home treatment. The individual device receives the pre-trained AI model, and runs the model in its own AI circuit. During treatment, the user can request a recommendation, such as a recommended blood flow profile, or the system can detect that the blood flow has an issue. For example, the blood flow rate can be too low to provide the desired therapy results, or a blood pressure sensor could indicate that the patient's blood pressure has dropped below a threshold, and thus, the blood flow rate should be decreased for the patient's health and safety.


Advantageously, by dividing the logic between two devices, the “heavy lifting” of the computations, such as parsing large volumes of data and training a model, can be performed on the backend in the cloud, where more processing power can be available. On the front end, at the dialysis machine, the pre-trained model can be run on the AI circuit, utilizing relatively fewer system resources. Although this split between workloads is illustrated as an example in this specification, one of skill will understand that any of the examples shown below, including the examples that explicitly show such a split, could also be applied to a system where all the processing occurs on a single device.


The analytical system disclosed herein uses a combination of analytical data obtained from various lab testing and history data for treatment parameters to identify and recommend a suggested blood flow rate for a patient, which can be delivered at each phase of a hemodialysis treatment delivery. Treatment parameters can include, by way of illustrative and nonlimiting example, patient access type, dialyzer type, therapy method, patient conditions, fluid removal, dialyzer permeability, patient weight, patient dry weight (e.g., a patient's weight before treatment), treatment time, treatment goals, or others. The system disclosed can provide multiple treatment parameter profile suggestions. This can allow the user to choose between a number of recommended ranges.


Furthermore, the system can suggest a recommended blood flow rate in the event of an adverse common condition during the treatment session. The patient or nurse can choose to accept or override a recommendation. For example, an adverse condition could include an unsafe drop in blood pressure. In that case, the system can suggest a change to the treatment parameters, such as the blood flow rate. The user can choose to accept or reject this recommendation, although in some embodiments, if the blood pressure or other parameter drops below an important threshold, the user selection can be overridden to protect the patient's life, health, or safety.


In at least some embodiments, the system suggests or automates the blood flow rate settings upon a user consensus, and/or in the event of adverse conditions, such as for low patient blood pressure. The system can also suggest or automate blood flow rates for common conditions that require changes in blood flow rate during hemodialysis delivery and blood return. In some cases, if the blood flow rate is changed (i.e., increased or decreased) during the treatment session, the system can dynamically predict a recommendation based on the changed blood flow rate, and provide that recommendation in real-time, or near real-time.


In further embodiments, the system can save the recommended blood flow rate profiles for a patient on the hemodialysis machine, or on a patient access card that is used to access and control the hemodialysis machine. This can include saving blood flow rate profiles for a home hemodialysis patient, or for in-clinic hemodialysis use.


Notably, although blood flow rate has been illustrated herein as an example parameter, the system can also be used to adjust other parameters, such as sodium profiles, ultrafiltration rate profiles, and other profiles that can influence dialysis adequacy.


may be surprised to learn that the reading material and the training do not translate directly into handling real-world issues during real treatment sessions. Issues could range from incorrect consumable installation, incorrect treatment parameter programming, incorrect medication, obstruction in the extracorporeal blood tube, incorrect handling of pressure alarms, and errors in treatment delivery.


Smart Therapy Analysis Module


As discussed above, a smart therapy analysis module is a software module that optionally can be hosted in the cloud. The smart therapy analysis module can be used to pre-train an AI model that can be executed on the home dialysis machine. This software can be provided with inputs that include analytical data. The analytical data can be obtained by lab regression testing of various treatment parameters, physiological parameters, adverse condition combinations, and the resultant clinical output. The treatment parameters could include, by way of illustrative and nonlimiting example, prescribed blood flow rate, treatment time, treatment goal, fluid to be removed, patient conditions, dialyzer type used, vascular access type, patient age, patient gender, patient physiological condition, patient treatment logs, or others. The clinical output data might include urea removed ratio/percentage and Kt/V over a time period.


The smart therapy software module can be used to analyze these factors, and provide a pre-trained AI model, or other inputs that can be used to control an AI model, which can be executed on the home therapy machine.


Artificial Intelligence Module


The home dialysis machine can include an AI module. The input for the AI module can include the data analytics from the smart therapy analysis module discussed above, which can be retrieved via a secure internet connection. Other inputs can include current treatment parameters entered on the user interface (UI), or parameters obtained in a safe and encrypted form from a cloud-based EHR repository. The AI circuit can compare the smart therapy and the current EHR data to provide a recommended high clearance prediction, and a recommended range of treatment parameters. The predictions and recommendations can be gathered using a basic machine learning regression model, or some other machine learning model. The regression model can identify patterns, relationships between different combinations of data, or other relationships. During a new treatment session, the model can suggest appropriate treatment parameters for high clearance and overall clinical output of the session. In some cases, current EHR details entered on the UI can be compared to lab result data analytics, to provide important treatment parameter adjustments for higher clearance.


The patient's blood sample may be measured to determine whether the dialysis has removed enough waste product from the blood. The patient's blood sample may be measured for dialysis adequacy periodically, including before dialysis starts, a month after dialysis is started, or twice a month during dialysis, by way of nonlimiting example. Factors that may be computed from these measurements include a urea reduction ratio (URR), and a clearance per treatment over water volume t. These are calculated from the patient's blood sample to assess the dialysis adequacy. Based on these values, a physician may update the treatment parameters to improve dialysis adequacy. To improve dialysis clearance K, the physician may attempt to optimize the rate at which blood flows through the dialyzer, referred to as the “blood flow rate.” If the blood flow is optimal, then the dialysis clearance rate is improved. However, the blood flow rate cannot be increased indiscriminately. Changing the blood flow rate may depend on factors including the maturity and strength of the patient's vascular access. The clearance may be adjusted by choosing the correct treatment parameters, such as dialyzer type, treatment time, treatment goal, patient's weight, patient conditions, and similar. Blood flow rate is a primary treatment parameter for the dialysis efficiency and efficacy. Fluctuations in the blood flow rate during the dialysis influence the dialysis clearance and the health of vascular access.


In some cases, in-center treatments are performed on average three times per week, usually for about four hours per session. Home hemodialysis may also be performed, depending on the type of therapy chosen. Long home therapy sessions may be performed three times a week (e.g., for four hours). Short treatments may be done five to six days a week, with shorter treatment times between three and four hours. Nocturnal treatments may be performed daily while the patient is asleep, for approximately six to seven hours.


Nurses can sign up for home therapy RN courses. A home therapy RN course could last for as many as six months. Home therapy nurses can also train home dialysis patients for home hemodialysis. However, as in the previous case, theory and training do not always translate directly to real-world issues, particularly for relatively new nurses. This can increase difficultly for the nurse to do his or her job, and also impact the nurse's ability to train home care patients. Often, nurses may meet different sets of patients with different adverse conditions. Nurses need to be able to adjust treatment parameters according to situations that arise during individual sessions. The nurse needs to handle real-time scenarios in a clinically appropriate fashion. Nurses may also be bombarded with questions from patients regarding programming and other parameters during the session.


The patient's blood may be monitored to determine whether the dialysis has removed enough waste product. A physician may update the treatment parameters to improve dialysis adequacy. However, the blood flow rate cannot be increased indiscriminately. Changing the blood flow rate may depend on factors including the maturity and strength of the patient's vascular access. The clearance may be adjusted by choosing the correct treatment parameters, such as dialyzer type, treatment time, treatment goal, patient's weight, patient conditions, and similar.


User Interface


In an embodiment, the recommended blood flow rate for improved dialysis clearance can be displayed and recommended in the form of a graph on the UI. Once the patient or home therapy nurse confirms the prescription treatment parameters from the EHR on the UI, the values can be predicted by the AI circuit disclosed above. In one example, the UI includes a “smart assist” UI button to display the recommendations on the UI. The treatment parameter prediction (e.g., blood flow rate) can be recommended on the UI during the entire treatment session. When data are displayed in a graphical form, in one embodiment, the highest point on the Y axis signifies the high blood flow rate. The highest point on the X axis signifies the treatment time. The system can display individual blood flow rate or a series of blood flow rates over the period of treatment. In the case of a plurality of blood flow rates, these can be saved as a blood flow rate profile.


In an embodiment, the patient or nurse can click on the blood flow rate points to accept a suggested value. The value can then be set in the treatment parameters, optionally with a double confirmation. The patient or nurse can also overwrite the blood flow rate suggestion with an edit option. For example, the patient can “drag” blood flow rate points to change the blood flow rate at a particular time in the course of treatment. If the patient is in doubt, the patient or nurse can check the profile, such as a stored profile, to decide on a course of treatment.


Advantageously, this reduces the cognitive load on the user. The system provides an option to save blood flow rate profiles for a patient on the hemodialysis device or a patient card. The saved profile in the patient card can be viewed or reviewed by a nephrologist or other doctor at the next appointment, and a prescription can be adjusted as necessary. This gives the nephrologist the ability to decide on the treatment parameters, without needing to skim through numerous data. The blood flow rate profiles or the recommended values might be logged for each treatment. These logs might be helpful in improving the AI model, and in some cases, results of treatment can be uploaded back to the cloud for further analysis by the smart software module. In some embodiments, these data are anonymized so that patient privacy is not compromised.


In the event of an adverse condition, a blood flow rate might be suggested to the user. Accepting this value during treatment can result in a dynamic suggestion or a change in blood flow rate instantaneously.


In an embodiment, the AI circuit can also have an interface to a voice-activated user prompt for patients with hearing and cognitive impairments. This can allow voice control to further ease patient operation.


Example User Interface Outputs



FIGS. 4 and 5 illustrate example outputs that can be provided on a user interface, as disclosed herein.


In the example of FIG. 4, user interface 400 provides a recommendation for a blood flow rate for high clearance for the device. This recommendation can be derived, for example, from an AI engine. The recommendation provides a blood flow rate profile that starts with a relatively low blood flow rate, ramps up to an intermediate blood flow rate at the beginning of treatment, reaches a peak approximately three-quarters through the treatment, and then ramps down to a relatively low blood flow rate at the end of treatment. In some cases, the user can operate the illustrated smart assist button to request a recommended blood flow rate.


As illustrated in FIG. 5, the user can accept the recommended blood flow rate displayed on user interface 500, or in some cases, as in the case of a touchscreen, the user can operate the touchscreen to change the recommended profile. For example, the user can operate the edit button illustrated, to edit the recommended blood flow rate. The user can then move individual points up and down, or left and right, to change the blood flow rate represented, and/or to change when that blood flow rate is used during the treatment. The user can then use the save button to save the selected blood flow rate.


Cloud Service and Medical Device Interaction



FIG. 6 is a block diagram illustrating interaction between a cloud service 601 and a medical device 603. In this example, cloud service 601 provides a trained or preprocessed AI model to medical device 603.


Cloud service 601 includes a cloud hardware platform 602, that collects various data referred to herein as static data 615. Static data 615 are so labeled because they are relatively static compared to the real-time, or near real-time, treatment data, which can change continuously during the course of treatment. In contrast, the static data are not expected to change during the course of treatment. Static data can include, by way of illustrative and nonlimiting example, treatment goals, prescription parameters, dialyzer type, patient physiology, patient lab report data, and patient medical history. Static data 615 can also be combined with EHR 606, which can contain historical patient data. These can then be provided to analysis module 604. Analysis module 604 can analyze static data 615 and EHR data 606, along with any other data that can be provided, such as data that are more applicable to a general population or class of people. Analysis module 604 uses these to create a trained or otherwise prepared AI model 612. Trained AI model 612 is ready to be run on an endpoint device, such as a specific medical device. In this example, trained AI model 612 is specific to the individual patient and the treatment conditions.


Analytical data for trained AI model 612 may be obtained, for example, by lab regression testing of various treatment parameters, physiological parameters, and adverse condition combinations. The resultant clinical outputs may be based on various patient data and biochemically-fabricated samples. The treatment parameters may include, by way of illustrative and nonlimiting example, prescribed blood flow rate, treatment time, treatment goal, fluid to be removed, patient conditions, dialyzer types used, vascular access type, patient's age and gender, patient physiological conditions, and patient treatment logs. The clinical output data might include urea removed ratio/percentage and Kt/V over a period


The input for the AI engine may include data analytics from software control module 620, and current treatment parameters entered on the user interface, or alternatively obtained in safe encrypted form from a cloud-based EHR service and/or picture archiving and communication system (PACS).


The proposed AI may then compare the smart therapy and the current EHR data to provide optimal high clearance predictions and recommendations ranges for the treatment parameters.


For example, the AI system may compare current EHR details (entered on the UI or retrieved from a service) against laboratory results data analytics, and a learning regression model from history data. The result may be a recommendation for critical treatment parameter adjustment for high clearance. Hyperparameter tuning may occur as part of the learning regression model.


The AI model predictions and recommendations may be gathered, in at least one embodiment, by using a machine learning regression model. The regression model may identify patterns and relations between different combination of data.


During a new treatment session, AI circuit 616 of medical device 603 may suggest appropriate treatment parameters for high clearance and overall clinical output of the session.


Trained AI model 612 is provided to medical device 603, which uses AI circuit 616 to process trained AI model 612. AI circuit 616 receives sensor inputs 624, such as via smart sensors connected to the home (e.g., smart scales, smart BP monitors, smart pulse oximeters, or other smart sensors), as well as manual user inputs, as necessary. AI circuit 616 also receives analytical data 632. Together, these form the inputs to AI circuit 616, which provides recommendations to software control module 620. Software control module 620 provides inputs and outputs to GUI 628, which can provide the recommendation to a user, and can receive an indication of whether the user has accepted the recommendation. Software control module 620 can then control therapeutic subsystem 640.


Method (As Performed, for Example, by a Cloud Service)



FIG. 7 is a flowchart of a method 700. Method 700 can be performed, for example, by a cloud service.


The method starts in block 704.


In block 706, the system collects patient historical data and other inputs that can be used to train or refine a model.


In block 708, the system applies an AI algorithm to pre-train a patient-specific model.


In block 710, the system publishes the patient-specific model to an individual device, such as by transferring the model via a secure network connection to the individual device.


In block 712, the system can receive treatment results or feedback from the individual device. These can also be received via a secure network connection.


In block 716, the system can optionally incorporate the feedback into the patient-specific model, and/or into more general models applicable to other patients.


In block 720, the system can republish the patient-specific model to the individual device. This republished model can include the incorporated feedback, and optionally, improvements derived from other patient data. The process of improvement can then continue in a loop between blocks 712 and 720.


Method (as Performed, for Example, by an Individual Therapeutic Device)



FIG. 8 is a flowchart of a method 800. Method 800 can be performed by the individual therapeutic device, such as a hemodialysis device.


Starting at block 804, in block 806 the system receives the patient-specific model from the cloud. For example, the system can operate a secure network connection to download the patient-specific model from a cloud service.


In block 808, the system runs the patient-specific model in a programmable circuit, such as an AI circuit.


In block 810, either autonomously or in response to a stimulus, such as the user pressing a smart assist button, the system provides a recommendation. The recommendation can include a suggested flow rate, or a suggested flow rate profile, by way of nonlimiting example.


In block 812, therapy commences. As therapy continues, the system can continuously monitor the patient to ensure that safety is maintained. For example, increasing the blood flow rate too high can help to increase clearance, but could cause the patient's blood pressure to drop dangerously low. Thus, in this example, a blood pressure sensor is used to monitor the patient's blood pressure. In other embodiments, other sensors could be used to monitor other parameters.


In decision block 816, if the blood pressure drops below a threshold, then control returns to block 808, where the system can use this new input to recalculate a recommended blood flow profile. The user can be given an opportunity to accept or reject this recommendation, unless the blood pressure drops dangerously low, in which case an automatic override can occur.


If the blood pressure remains above the threshold, then looping back to block 812, therapy continues until the therapy is complete.


In block 820, the therapy ends. For example, block 820 can represent the end of a 3-to-4-hour hemodialysis session.


In block 824, optionally, the patient's therapeutic results from this session can be uploaded back to the cloud service to help further improve the model. Note that for the purpose of improving a patient-specific model, the therapeutic results should be associated with the individual patient. However, one of skill will understand that the data can be aggregated from one or more patients to improve the general model. The data can be anonymized to preserve patient privacy.


In block 890, the method is done.


Network Function Virtualization (NFV) Infrastructure



FIG. 9 is a block diagram of an NFV infrastructure 900. FIG. 9 illustrates a platform for providing virtualization services. Virtualization can be used in some embodiments to provide one or more features of the present disclosure.


NFV is an aspect of network virtualization that is generally considered distinct from, but that can still interoperate with, software-defined networking (SDN). For example, virtual network functions (VNFs) can operate within the data plane of an SDN deployment. NFV was originally envisioned as a method for providing reduced capital expenditure (Capex) and operating expenses (Opex) for telecommunication services.


One feature of NFV is replacing proprietary, special-purpose hardware appliances with virtual appliances running on commercial off-the-shelf (COTS) hardware within a virtualized environment. In addition to Capex and Opex savings, NFV provides a more agile and adaptable network. As network loads change, VNFs can be provisioned (“spun up”) or removed (“spun down”) to meet network demands. For example, in times of high load, more load balancing VNFs can be spun up to distribute traffic to more workload servers (which can themselves be virtual machines). In times when more suspicious traffic is experienced, additional firewalls or deep packet inspection (DPI) appliances can be needed.


Because NFV started out as a telecommunications feature, many NFV instances are focused on telecommunications. However, NFV is not limited to telecommunication services. In a broad sense, NFV includes one or more VNFs running within a network function virtualization infrastructure (NFVI), such as NFVI 900. Often, the VNFs are inline service functions that are separate from workload servers or other nodes. These VNFs can be chained together into a service chain, which can be defined by a virtual subnetwork, and which can include a serial string of network services that provide behind-the-scenes work, such as security, logging, billing, and similar.


In the example of FIG. 9, an NFV orchestrator 901 manages a number of the VNFs 912 running on an NFVI 900. NFV requires nontrivial resource management, such as allocating a very large pool of compute resources among appropriate numbers of instances of each VNF, managing connections between VNFs, determining how many instances of each VNF to allocate, and managing memory, storage, and network connections. This can require complex software management, thus making NFV orchestrator 901 a valuable system resource. Note that NFV orchestrator 901 can provide a browser-based or graphical configuration interface, and in some embodiments can be integrated with SDN orchestration functions.


Note that NFV orchestrator 901 can be virtualized (rather than a special-purpose hardware appliance). NFV orchestrator 901 can be integrated within an existing SDN system, wherein an operations support system (OSS) manages the SDN. This can interact with cloud resource management systems (e.g., OpenStack) to provide NFV orchestration. An NFVI 900 can include the hardware, software, and other infrastructure to enable VNFs to run. This can include a hardware platform 902 on which one or more VMs 904 can run. For example, hardware platform 902-1 in this example runs VMs 904-1 and 904-2. Hardware platform 902-2 runs VMs 904-3 and 904-4. Each hardware platform can include one or more hypervisor 920-1, virtual machine manager (VMM), or similar function, which can include and run on a native (bare metal) operating system, which can be minimal so as to consume very few resources.


Hardware platforms 902-1 or 902-2 can be or comprise a rack or several racks of blade or slot servers (including, e.g., processors, memory, and storage), one or more data centers, other hardware resources distributed across one or more geographic locations, hardware switches, or network interfaces. An NFVI 900 can also include the software architecture that enables hypervisors to run and be managed by NFV orchestrator 901.


Running on NFVI 900 are a number of VMs 904, each of which in this example is a VNF providing a virtual service appliance. Each VM 904 in this example includes an instance of the Data Plane Development Kit (DPDK), a virtual operating system 908, and an application providing the VNF 912 including VNF-1912-1, VNF-2912-2, VNF-3912-3, VNF-4912-4. Any number of additional VNF can be provided, as required. The virtual operating system 908 can include Virtual OS 908-1, Virtual OS 908-2, Virtual OS 908-3, Virtual OS 908-4, or any number of additional virtual operating systems as required.


Virtualized network functions could include, as nonlimiting and illustrative examples, firewalls, intrusion detection systems, load balancers, routers, session border controllers, DPI services, network address translation (NAT) modules, or call security association.


The illustration of FIG. 9 shows that a number of VNFs 912 have been provisioned and exist within NFVI 900. FIG. 9 does not necessarily illustrate any relationship between the VNFs and the larger network, or the packet flows that NFVI 900 can employ.


The illustrated collective DPDK instances 916-1, 916-2, 916-3, and 916-4 provide a set of optimized libraries for communicating across a virtual switch (vSwitch) 922. DPDK 916-1 and DPDK 916-2 can be associated with hardware platform 902-1. DPDK 916-3 and DPDK 916-4 can be associated with hardware platform 902-2. Like VMs 904-3 and 904-4, switch 922 can be provisioned and allocated by a hypervisor 920-1. The hypervisor uses a network interface to connect the hardware platform to the data center fabric (e.g., a host fabric interface (HFI)). This HFI can be shared by all VMs 904-1, 904-2, 904-3, and 904-4 running on the hardware platform 902-1 or hardware platform 902-2. Thus, the vSwitch can be allocated to switch traffic between VMs 904. The vSwitch can be a pure software vSwitch (e.g., a shared memory vSwitch), which can be optimized so that data are not moved between memory locations, but rather, the data can stay in one place, and pointers can be passed between VMs 904 to simulate data moving between ingress and egress ports of the vSwitch. The vSwitch can also include a hardware driver (e.g., a hardware network interface intellectual property (IP) block that switches traffic, but that connects to virtual ports rather than physical ports). In this illustration, a distributed vSwitch 922 is illustrated, wherein vSwitch 922 is shared between two or more physical hardware platforms 902.


One skilled in the art will understand that various combinations and/or modifications and variations can be made in the described systems and methods depending upon the specific needs for operation. Various aspects disclosed herein can be combined in different combinations than the combinations specifically presented in the description and accompanying drawings. Moreover, features illustrated or described as being part of an aspect of the disclosure can be used in the aspect of the disclosure, either alone or in combination, or follow a preferred arrangement of one or more of the described elements. Depending on the example, certain acts or events of any of the processes or methods described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., certain described acts or events cannot be necessary to carry out the techniques). In addition, while certain aspects of this disclosure are described as performed by a single module or unit for purposes of clarity, the techniques of this disclosure can be performed by a combination of units or modules associated with, for example, a device.

Claims
  • 1. A medical device, comprising: a therapeutic subsystem to deliver a medical therapy, including a sensor to monitor a biometric health factor;a user interface;a controller, including a processor and a memory;therapy software comprising instructions encoded within the memory to instruct the processor to receive a prescribed therapy, to receive a therapeutic setting recommendation, and to display the therapeutic setting recommendation to an operator via the user interface;a network interface, and instructions to receive, via the network interface, a prepared artificial intelligence (AI) model from a cloud service; andan AI circuit having execution hardware comprising at least one logic gate, and further comprising instructions to instruct the execution hardware to execute the prepared AI model to provide a recommended therapy setting for the therapeutic subsystem, wherein the AI circuit is incorporated into the prepared AI model data from the sensor.
  • 2. The medical device of claim 1, wherein the execution hardware includes the processor.
  • 3. The medical device of claim 1, wherein the medical device is selected from an insulin pump, a continuous positive airway pressure machine, an external neural stimulator, an intravenous fluid device, and a dialysis machine.
  • 4. The medical device of claim 1, wherein the medical device is a dialysis machine.
  • 5. The medical device of claim 4, wherein the prepared AI model incorporates input selected from analytical data from laboratory testing, historical treatment parameters, patient access type, dialyzer type, therapy method, patient condition, fluid removal, dialyzer permeability, patient weight, dry weight, treatment time, and treatment goal.
  • 6. The medical device of claim 4, wherein the therapy setting recommendation comprises a blood flow rate recommendation.
  • 7. The medical device of claim 6, wherein the therapy software instructions are further to automatically select a recommended blood flow rate.
  • 8. The medical device of claim 6, wherein the therapy software instructions are further to detect a changed blood flow rate during therapy, and wherein the AI circuit is further to predict a recommendation according to the changed blood flow rate.
  • 9. The medical device of claim 6, wherein the sensor detects an adverse condition, and wherein the AI circuit recommends a blood flow rate according to the adverse condition.
  • 10. The medical device of claim 9, wherein the adverse condition includes low patient blood pressure.
  • 11. The medical device of claim 6, wherein the therapy software instructions are further to save one or more blood flow rate profiles for a patient.
  • 12. The medical device of claim 4, wherein the therapeutic setting recommendation is selected from blood flow rate, sodium profile, and ultrafiltration rate profile.
  • 13. The medical device of claim 1, wherein the user interface includes a control to request a therapeutic setting recommendation.
  • 14. The medical device of claim 1, wherein the user interface includes one or more controls to automatically accept or reject recommended therapeutic settings.
  • 15. The medical device of claim 1, wherein the therapy software instructions are further to download the treatment parameters from a cloud service.
  • 16. The medical device of claim 1, wherein the AI circuit is to provide a high clearance prediction.
  • 17. The medical device of claim 1, wherein the AI circuit is further to concurrently provide a plurality of recommended therapeutic settings.
  • 18. The medical device of claim 1, wherein the AI circuit provides an AI model selected from the group consisting of linear regression, logistic regression, linear discriminant analysis, decision tree, naïve Bayes, k-nearest neighbors, learning vector quantization, support vector machine, random forest, neural network, convolutional neural network, and deep neural network.
  • 19. A system, comprising the medical device of claim 1, and further comprising a cloud service, the cloud service comprising a hardware platform comprising a processor and a memory, and instructions encoded within the memory to instruct the processor to receive a plurality of historical patient inputs and build the prepared model from the plurality of historical patient inputs.
  • 20. The system of claim 19, wherein the prepared model is a patient-specific model.
US Referenced Citations (369)
Number Name Date Kind
3602222 Herndon Aug 1971 A
3608729 Haselden Sep 1971 A
3669878 Marantz Jun 1972 A
3669880 Marantz Jun 1972 A
3730183 Goldsmith May 1973 A
3754867 Guenther Aug 1973 A
3850835 Marantz Nov 1974 A
3884808 Scott May 1975 A
3989622 Marantz Nov 1976 A
3989625 Mason Nov 1976 A
4060485 Eaton Nov 1977 A
4371385 Johnson Feb 1983 A
4374382 Markowitz Feb 1983 A
4381999 Boucher May 1983 A
4460555 Thompson Jul 1984 A
4556063 Thompson Dec 1985 A
4562751 Nason Jan 1986 A
4581141 Ash Apr 1986 A
4650587 Polak Mar 1987 A
4661246 Ash Apr 1987 A
4678408 Mason Jul 1987 A
4685903 Cable Aug 1987 A
4747822 Peabody May 1988 A
4750494 King Jun 1988 A
4772560 Attar Sep 1988 A
4799493 DuFault Jan 1989 A
4826663 Alberti May 1989 A
4828693 Lindsay May 1989 A
4976683 Gauthier Dec 1990 A
5032265 Jha Jul 1991 A
5080653 Voss Jan 1992 A
5091642 Chow Feb 1992 A
5092838 Faict Mar 1992 A
5092886 Dobos-Hardy Mar 1992 A
5097122 Coiman Mar 1992 A
5127404 Wyborny Jul 1992 A
5141493 Jacobsen Aug 1992 A
5284470 Beltz Feb 1994 A
5302288 Meidl Apr 1994 A
5305745 Zacouto Apr 1994 A
5318750 Lascombes Jun 1994 A
5364593 Mihaylov Nov 1994 A
5415838 Rieger May 1995 A
5468388 Goddard Nov 1995 A
5507723 Keshaviah Apr 1996 A
5643201 Peabody Jul 1997 A
5651893 Kenley Jul 1997 A
5683432 Goedeke Nov 1997 A
5744031 Bene Apr 1998 A
5762782 Kenley Jun 1998 A
5819007 Elghazzawi Oct 1998 A
5902336 Mishkin May 1999 A
5944684 Roberts Aug 1999 A
5987352 Klein Nov 1999 A
6042721 Peters Mar 2000 A
6048732 Anslyn Apr 2000 A
6052622 Holmstrom Apr 2000 A
6058331 King May 2000 A
6156002 Polaschegg Dec 2000 A
6230059 Duffin May 2001 B1
6248093 Moberg Jun 2001 B1
6254567 Treu Jul 2001 B1
6321101 Holmstrom Nov 2001 B1
6362591 Moberg Mar 2002 B1
6363279 Ben-Haim Mar 2002 B1
6505075 Weiner Jan 2003 B1
6554798 Mann Apr 2003 B1
6555986 Moberg Apr 2003 B2
6589229 Connelly Jul 2003 B1
6602399 Fromherz Aug 2003 B1
6609023 Fischell Aug 2003 B1
6627164 Wong Sep 2003 B1
6645191 Knerr Nov 2003 B1
6676608 Keren Jan 2004 B1
6689083 Gelfand Feb 2004 B1
6706007 Gelfand Mar 2004 B2
6711439 Bradley Mar 2004 B1
6726647 Sternby Apr 2004 B1
6780322 Bissler Aug 2004 B1
6818196 Wong Nov 2004 B2
6878283 Thompson Apr 2005 B2
6887214 Levin May 2005 B1
6890315 Levin May 2005 B1
6960179 Gura Nov 2005 B2
7074332 Summerton Jul 2006 B2
7077819 Goldau Jul 2006 B1
7131956 Pirazzoli Nov 2006 B1
7175809 Gelfand Feb 2007 B2
7207946 Sirokman Apr 2007 B2
7208092 Micheli Apr 2007 B2
7276042 Polaschegg Oct 2007 B2
7399289 Gelfand Jul 2008 B2
7404799 Koh Jul 2008 B1
7500958 Asbrink Mar 2009 B2
7566432 Wong Jul 2009 B2
7575564 Childers Aug 2009 B2
7610086 Ke Oct 2009 B1
7674231 McCombie Mar 2010 B2
7704361 Garde Apr 2010 B2
7736507 Wong Jun 2010 B2
7744553 Kelly Jun 2010 B2
7754852 Burnett Jul 2010 B2
7756572 Fard Jul 2010 B1
7775983 Zhang Aug 2010 B2
7775986 Roeher Aug 2010 B2
7776210 Rosenbaum Aug 2010 B2
7785463 Bissler Aug 2010 B2
7794141 Perry Sep 2010 B2
7850635 Polaschegg Dec 2010 B2
7857976 Bissler Dec 2010 B2
7867214 Childers Jan 2011 B2
7896831 Sternby Mar 2011 B2
7922686 Childers Apr 2011 B2
7922911 Micheli Apr 2011 B2
7947179 Rosenbaum May 2011 B2
7955291 Sternby Jun 2011 B2
7967022 Grant Jun 2011 B2
7981082 Wang Jul 2011 B2
8000000 Greenberg Aug 2011 B2
8034161 Gura Oct 2011 B2
8070709 Childers Dec 2011 B2
8096969 Roberts Jan 2012 B2
8105260 Tonelli Jan 2012 B2
8202503 Putnam Feb 2012 B2
8183046 Lu May 2012 B2
8187250 Roberts May 2012 B2
8197439 Wang Jun 2012 B2
8202241 Karakama Jun 2012 B2
8246826 Wilt Aug 2012 B2
8273049 Demers Sep 2012 B2
8282828 Wallenas Oct 2012 B2
8292594 Tracey Oct 2012 B2
8313642 Yu Nov 2012 B2
8317492 Demers Nov 2012 B2
8357113 Childers Jan 2013 B2
8366316 Kamen Feb 2013 B2
8366655 Kamen Feb 2013 B2
8404091 Ding Mar 2013 B2
8409441 Wilt Apr 2013 B2
8496809 Roger Jul 2013 B2
8499780 Wilt Aug 2013 B2
8500676 Jansson Aug 2013 B2
8512271 Moissl Aug 2013 B2
8518260 Raimann Aug 2013 B2
8521482 Akonur Aug 2013 B2
8535525 Heyes Sep 2013 B2
8560510 Brueggerhoff Oct 2013 B2
8580112 Updyke Nov 2013 B2
8597227 Childers Dec 2013 B2
8696626 Kirsch Apr 2014 B2
8903492 Soykan Dec 2014 B2
8926542 Gerber Jan 2015 B2
9700663 Burbank Jul 2017 B2
9907897 Burbank Mar 2018 B2
10076599 Eyrard Sep 2018 B2
10076735 Jansson Sep 2018 B2
10173881 Beavis Jan 2019 B2
10459459 Beavis Oct 2019 B2
10478544 Friederichs Nov 2019 B2
10610630 Burbank Apr 2020 B2
20010048637 Weigl Dec 2001 A1
20020016550 Sweeney Feb 2002 A1
20020042561 Schulman Apr 2002 A1
20020112609 Wong Aug 2002 A1
20030028089 Galley Apr 2003 A1
20030069481 Hervy Apr 2003 A1
20030080059 Peterson May 2003 A1
20030097086 Gura May 2003 A1
20030105435 Taylor Jun 2003 A1
20030113931 Pan Jun 2003 A1
20030114787 Gura Jun 2003 A1
20030187479 TranThong Oct 2003 A1
20040019312 Childers Jan 2004 A1
20040060865 Callan Apr 2004 A1
20040068219 Summerton Apr 2004 A1
20040099593 DePaolis May 2004 A1
20040147900 Polaschegg Jul 2004 A1
20040168969 Sternby Sep 2004 A1
20040215090 Erkkila Oct 2004 A1
20050065760 Murtfeldt Mar 2005 A1
20050113796 Taylor May 2005 A1
20050126961 Bissler Jun 2005 A1
20050131331 Kelly Jun 2005 A1
20050126998 Childers Jul 2005 A1
20050150832 Tsukamoto Jul 2005 A1
20050214863 McDevitt Sep 2005 A1
20050234354 Rowlandson Oct 2005 A1
20050234357 Xue Oct 2005 A1
20050234381 Niemetz Oct 2005 A1
20050234534 Rowlandson Oct 2005 A1
20050236330 Nier Oct 2005 A1
20050265895 Kopelman Dec 2005 A1
20050274658 Rosenbaum Dec 2005 A1
20060025661 Sweeney Feb 2006 A1
20060025748 Ye Feb 2006 A1
20060217771 Soykan Feb 2006 A1
20060058731 Burnett Mar 2006 A1
20060191850 Bosetto Aug 2006 A1
20060195064 Plahey Aug 2006 A1
20060226079 Mori Oct 2006 A1
20060241709 Soykan Oct 2006 A1
20060247548 Sarkar Nov 2006 A1
20060264894 Moberg Nov 2006 A1
20070007208 Brugger Jan 2007 A1
20070031972 Attar Feb 2007 A1
20070038138 Gill Feb 2007 A1
20070066928 Lannoy Mar 2007 A1
20070073168 Zhang Mar 2007 A1
20070138011 Hofmann Jun 2007 A1
20070161113 Ash Jul 2007 A1
20070175827 Wariar Aug 2007 A1
20070179431 Roberts Aug 2007 A1
20070213653 Childers Sep 2007 A1
20070215545 Bissler Sep 2007 A1
20070222992 Oda Sep 2007 A1
20070255250 Moberg Nov 2007 A1
20070276270 Tran Nov 2007 A1
20080006570 Gura Jan 2008 A1
20080021337 Li Jan 2008 A1
20080053905 Brugger Mar 2008 A9
20080067132 Ross Mar 2008 A1
20080093276 Roger Apr 2008 A1
20080200866 Prisco Aug 2008 A1
20080215247 Tonelli Sep 2008 A1
20080233008 Sarkisov Sep 2008 A1
20080253427 Kamen Oct 2008 A1
20090020471 Tsukamoto Jan 2009 A1
20090036825 Petersen Feb 2009 A1
20090101577 Fulkerson Apr 2009 A1
20090124869 Hu May 2009 A1
20090124963 Hogard May 2009 A1
20090127193 Updyke May 2009 A1
20090149776 Adams Jun 2009 A1
20090171261 Sternby Jul 2009 A1
20090264776 Vardy Oct 2009 A1
20090275849 Stewart Nov 2009 A1
20090275883 Chapman Nov 2009 A1
20090281484 Childers Nov 2009 A1
20090282980 Gura Nov 2009 A1
20090287467 Sparks Nov 2009 A1
20090314063 Sternby Dec 2009 A1
20100004588 Yeh Jan 2010 A1
20100010425 Yu Jan 2010 A1
20100010429 Childers Jan 2010 A1
20100042035 Moissl Feb 2010 A1
20100061892 Flaim Mar 2010 A1
20100076398 Scheurer Mar 2010 A1
20100078381 Merchant Apr 2010 A1
20100078387 Wong Apr 2010 A1
20100084330 Wong Apr 2010 A1
20100087771 Karakama Apr 2010 A1
20100094158 Solem Apr 2010 A1
20100113891 Barrett May 2010 A1
20100114012 Sandford May 2010 A1
20100137693 Porras Jun 2010 A1
20100137782 Jansson Jun 2010 A1
20100168546 Kamath Jul 2010 A1
20100217180 Akonur Aug 2010 A1
20100217181 Roberts Aug 2010 A1
20100224492 Ding Sep 2010 A1
20100234795 Wallenas Sep 2010 A1
20100241045 Kelly Sep 2010 A1
20100264086 Noack Oct 2010 A1
20100312172 Hoffman Dec 2010 A1
20110017665 Updyke Jan 2011 A1
20110048949 Ding et al. Mar 2011 A1
20110066006 Banet Mar 2011 A1
20110066043 Banet Mar 2011 A1
20110071465 Wang Mar 2011 A1
20110077574 Sigg Mar 2011 A1
20110077575 Kraemer Mar 2011 A1
20110079558 Raimann Apr 2011 A1
20110081728 Putnam Apr 2011 A1
20110087187 Beck Apr 2011 A1
20110100909 Stange May 2011 A1
20110106003 Childers May 2011 A1
20110130666 Dong Jun 2011 A1
20110137136 Kotanko Jun 2011 A1
20110141116 Dalesch Jun 2011 A1
20110144570 Childers Jun 2011 A1
20110184340 Tan Jul 2011 A1
20110208105 Brandl Aug 2011 A1
20110272337 Palmer Nov 2011 A1
20110301447 Park Dec 2011 A1
20110301472 Grober Dec 2011 A1
20120016228 Kroh Jan 2012 A1
20120029937 Neftel Feb 2012 A1
20120083729 Childers Apr 2012 A1
20120085707 Beiriger Apr 2012 A1
20120115248 Ansyln May 2012 A1
20120135396 McDevitt May 2012 A1
20120181230 Kloeffel Jul 2012 A1
20120220528 VanAntwerp Aug 2012 A1
20120258545 Ash Oct 2012 A1
20120258546 Marran Oct 2012 A1
20120259276 Childers Oct 2012 A1
20120273354 Soykan Nov 2012 A1
20120273415 Gerber Nov 2012 A1
20120273420 Gerber Nov 2012 A1
20120277546 Soykan Nov 2012 A1
20120277551 Gerber Nov 2012 A1
20120277552 Gerber Nov 2012 A1
20120277604 Gerber Nov 2012 A1
20120277650 Gerber Nov 2012 A1
20120277655 Gerber Nov 2012 A1
20120277722 Gerber Nov 2012 A1
20120283581 Olde et al. Nov 2012 A1
20120303079 Mahajan Nov 2012 A1
20130037465 Heyes Feb 2013 A1
20130062265 Balschat Mar 2013 A1
20130116578 QiAn May 2013 A1
20130168316 Noguchi Jul 2013 A1
20130186759 Lin Jul 2013 A1
20130193073 Hogard Aug 2013 A1
20130199998 Kelly Aug 2013 A1
20130211730 Wolff Aug 2013 A1
20130213890 Kelly Aug 2013 A1
20130228517 Roger Sep 2013 A1
20130231607 Roger Sep 2013 A1
20130248426 Pouchoulin Sep 2013 A1
20130274642 Soykan Oct 2013 A1
20130324915 Britton Dec 2013 A1
20130330208 Ly Dec 2013 A1
20130331774 Farrell Dec 2013 A1
20140018727 Burbank Jan 2014 A1
20140018728 Plahey Jan 2014 A1
20140042092 Akonur Feb 2014 A1
20140065950 Mendelsohn Mar 2014 A1
20140088442 Soykan Mar 2014 A1
20140110340 White Apr 2014 A1
20140110341 White Apr 2014 A1
20140158538 Collier Jun 2014 A1
20140158588 Pudil Jun 2014 A1
20140158623 Pudil Jun 2014 A1
20140190876 Meyer Jul 2014 A1
20140216250 Meyer Aug 2014 A1
20140217028 Pudil Aug 2014 A1
20140217029 Meyer Aug 2014 A1
20140217030 Meyer Aug 2014 A1
20140220699 Pudil Aug 2014 A1
20140276100 Satterfield Sep 2014 A1
20140314625 Clift Oct 2014 A1
20150032023 Soykan Jan 2015 A1
20150080682 Gerber Mar 2015 A1
20150088047 Gerber Mar 2015 A1
20150144539 Pudil May 2015 A1
20150148697 Burnes May 2015 A1
20150149096 Soykan May 2015 A1
20150250427 Soykan Sep 2015 A1
20150343126 Merchant Dec 2015 A1
20150352269 Gerber Dec 2015 A1
20150367054 Gerber Dec 2015 A1
20160023467 Smith Feb 2016 A1
20160143774 Burnett May 2016 A1
20160166753 Meyer Jun 2016 A1
20160206801 Gerber Jul 2016 A1
20160331884 Sigg Nov 2016 A1
20170319768 Szpara Nov 2017 A1
20170364660 Vigersky Dec 2017 A1
20180043080 Gerber Feb 2018 A1
20180221555 Rohde Aug 2018 A1
20190125952 Jansson May 2019 A1
20190125954 Mathiot May 2019 A1
20190151526 Wieslander May 2019 A1
20190240389 Rohde Aug 2019 A1
20200019823 Wang Jan 2020 A1
20200282218 McDonald Sep 2020 A1
20220031947 Onesti Feb 2022 A1
20220051773 Appelbaum Feb 2022 A1
Foreign Referenced Citations (169)
Number Date Country
3149888 Mar 2021 CA
1643368 Jul 2005 CN
101193667 Jun 2008 CN
101300476 Nov 2008 CN
101400997 Jan 2009 CN
101482572 Jul 2009 CN
201342127 Nov 2009 CN
101726465 Jun 2010 CN
202048893 Mar 2011 CN
103037917 Apr 2013 CN
103180712 Jun 2013 CN
103339503 Oct 2013 CN
103394139 Nov 2013 CN
103619372 Mar 2014 CN
103751871 Apr 2014 CN
103803479 May 2014 CN
103901025 Jul 2014 CN
104174077 Dec 2014 CN
104685342 Jun 2015 CN
104833635 Aug 2015 CN
105008893 Oct 2015 CN
105115921 Dec 2015 CN
105142692 Dec 2015 CN
105692957 Jun 2016 CN
105928939 Jul 2016 CN
106124491 Nov 2016 CN
205672288 Nov 2016 CN
107206147 Sep 2017 CN
110415831 Nov 2019 CN
101644667 Feb 2020 CN
212619551 Feb 2021 CN
3224823 Jan 1984 DE
102006028172 Dec 2017 DE
0266795 Nov 1987 EP
0402505 Dec 1990 EP
0272414 Oct 1991 EP
0330892 Jul 1994 EP
1175238 Nov 2000 EP
1085295 Nov 2001 EP
1281351 Feb 2003 EP
2308526 Oct 2003 EP
1364666 Nov 2003 EP
1523347 Jan 2004 EP
1523350 Jan 2004 EP
0906768 Feb 2004 EP
1691863 Apr 2005 EP
2116269 Feb 2008 EP
1450879 Oct 2008 EP
1514562 Apr 2009 EP
2219703 May 2009 EP
1592494 Jun 2009 EP
2398529 Nov 2010 EP
2575827 Dec 2010 EP
2100553 Aug 2011 EP
2576453 Dec 2011 EP
2701580 Nov 2012 EP
2701595 Nov 2012 EP
1345856 Mar 2013 EP
2344220 Apr 2013 EP
1351756 Jul 2013 EP
2190498 Jul 2013 EP
2701596 Mar 2014 EP
1582226 Jan 2016 EP
S55138462 Oct 1980 JP
S63-143077 Nov 1987 JP
2002533170 Oct 2002 JP
2002542900 Dec 2002 JP
2003235965 Aug 2003 JP
2005-533573 Nov 2005 JP
5-99464 Oct 2012 JP
20010109443 Dec 2001 KR
WO1992005814 Apr 1992 WO
1995003839 Feb 1995 WO
WO 1998054563 Dec 1998 WO
WO1999006082 Feb 1999 WO
9937342 Jul 1999 WO
PCT1124599 May 2000 WO
0057935 Oct 2000 WO
WO2000057935 Oct 2000 WO
2000066197 Nov 2000 WO
200170307 Sep 2001 WO
2001085295 Sep 2001 WO
0185295 Nov 2001 WO
2002013691 Feb 2002 WO
WO 20020053211 Jul 2002 WO
2003043677 May 2003 WO
2003043680 May 2003 WO
2003051422 Jun 2003 WO
2004008826 Jan 2004 WO
2004009156 Jan 2004 WO
2004009158 Jan 2004 WO
2004030716 Apr 2004 WO
2004030717 Apr 2004 WO
2004064616 Aug 2004 WO
2005033701 Apr 2005 WO
2005061026 Jul 2005 WO
2005123230 Dec 2005 WO
2006011009 Feb 2006 WO
2006017446 Feb 2006 WO
2007038347 Apr 2007 WO
2007089855 Aug 2007 WO
20070115321 Oct 2007 WO
WO2009094035 Jan 2008 WO
2008037410 Apr 2008 WO
2009026603 Dec 2008 WO
2009024566 Feb 2009 WO
2009026603 Mar 2009 WO
2009061608 May 2009 WO
2009094184 Jul 2009 WO
2009157877 Dec 2009 WO
2009157878 Dec 2009 WO
WO2009154955 Dec 2009 WO
WO 20090154955 Dec 2009 WO
2010024963 Mar 2010 WO
2010028860 Mar 2010 WO
2010033314 Mar 2010 WO
2010033699 Mar 2010 WO
2010077851 Jul 2010 WO
2010096659 Oct 2010 WO
2010121820 Oct 2010 WO
2011025705 Mar 2011 WO
2011026645 Mar 2011 WO
WO2013022760 Aug 2011 WO
WO 2011132046 Oct 2011 WO
2011137693 Nov 2011 WO
WO2011161056 Dec 2011 WO
2012042323 Apr 2012 WO
2012050781 Apr 2012 WO
2012051996 Apr 2012 WO
2012073420 Jul 2012 WO
WO 2012129501 Sep 2012 WO
2012148781 Nov 2012 WO
2012148784 Nov 2012 WO
2012148786 Nov 2012 WO
2012148787 Nov 2012 WO
2012148789 Nov 2012 WO
2012162515 Nov 2012 WO
WO2012148788 Nov 2012 WO
WO 20120148784 Nov 2012 WO
2012172398 Dec 2012 WO
2013019179 Feb 2013 WO
2013019994 Feb 2013 WO
2013025844 Feb 2013 WO
2013028809 Feb 2013 WO
2013101292 Jul 2013 WO
2013103607 Jul 2013 WO
2013103906 Jul 2013 WO
2013110906 Aug 2013 WO
2013110919 Aug 2013 WO
2013114063 Aug 2013 WO
2013121162 Aug 2013 WO
2013140346 Sep 2013 WO
2013141896 Sep 2013 WO
14066254 May 2014 WO
14066255 May 2014 WO
14077082 May 2014 WO
2014121162 Aug 2014 WO
2014121163 Aug 2014 WO
2014121167 Aug 2014 WO
2014121169 Aug 2014 WO
WO2014121161 Aug 2014 WO
WO 20140121161 Aug 2014 WO
WO 20140121169 Aug 2014 WO
WO2015081221 Jun 2015 WO
WO 20150130205 Sep 2015 WO
WO 20150159280 Oct 2015 WO
WO 20160080883 May 2016 WO
WO 20170034452 Mar 2017 WO
WO 2017176687 Oct 2017 WO
Non-Patent Literature Citations (149)
Entry
Heiko Hickstein, Et Al; “Clinical application of fuzzy-controlled blood pressure stabilization in patients prone to hypotension duirng hemodiaylsis”, Dyalysis & Transplantation, vol. 38, No. 2, Feb. 1, 2009, pp. 58-64.
Henderson, et al, “Online Preparation of Sterile Pyrogen-Free Electrolyte Solution,” Trans. Am. Soc. Artif. Intern.Organs, 1978 pp. 465-467.
Indian OA of Nov. 21, 2019 in 2981/KOLNP/2013.
Indian Office Action for Application 201714030219, dated May 31, 2021.
International Preliminary Report on Patentability for App. No. PCT/US2019/019334, dated Jun. 12, 2019.
Laurent, Jeanpierre, “Continuous Monitoring of Dynamic Systems: Application to Monitoring of Dialyzed Patients” Oct. 30, 2004, received from internet: http://laurent.jeanpierre1.free.fr/recherche/papiers/aista2004.pdf.
Office Action for Chinese Application No. 201710779349.3, dated Oct. 9, 2019.
Office Action for European App. No. 17190066.5, dated Mar. 7, 2019.
Office Action for European App. No. 17718241.7, dated Apr. 2, 2020.
Office Action in Chinese App. No. 201710778666.3 dated Sep. 19, 2019.
Office Action in Chinese App. No. 201780019238.0, dated Sep. 25, 2020.
PCT/US2016/058579 International Search Report dated Jan. 31, 2017.
PCT/US2016/058579 Written Opinion dated Jan. 31, 2017.
PCT/US2017/025868 International Search Report dated Jun. 29, 2017.
PCT/US2017/025868 Written Opinion dated Jun. 29, 2017.
PCT/US2017/030377 International Search Report dated Sep. 1, 2017.
PCT/US2017/030377 Written Opinion dated Sep. 1, 2017.
PCTUS20170146199 ISR and written opinion, Feb. 19, 2018.
PCTUS2017025858 International Search Report dated Jun. 29, 2017.
PCTUS2017025858 Written Opinion dated Jun. 29, 2017.
PCTUS2017025876 International Search Report dated Jun. 29, 2017.
PCTUS2017025876 Written Opinion dated Jun. 29, 2017.
Schmitt, et al, “Colorimetric Gas Sensing with Enhanced Sensitivity,” Procedia Engineering, vol. 168, Sep. 3, 2016, pp. 1237-1240.
Second Chinese Office Action for Application No. 201811107614.4, dated Apr. 15, 2021.
Wollenstein, et al, “Colorimetric gas sensors for the detection of ammonia, nitrogen dioxide, and carbon monoxide: current status and research trends”, Sensor and Test Conference 2011, Jan. 2, 2011, pp. 562-567.
Written Opinion in Dutch App. No. 2018577, dated Nov. 2, 2017.
€œ Resources, environment and sustainable development of agriculture,â€⋅ edited by Liu Zhaopu, China Agricultural Science and Technology Press, pp. 209-211, Aug. 31, 1994.
€œ Rural Medical and Health Handbook, â€⋅ written by Shanghai “Rural Medical and Health Handbook Writing team, Shanghai Science and Technology Press, Jun. 1968, p. 435.
€œSurface water environmental quality standard non-ionic ammonia conversion method, â€⋅ Teng Enjiang, et al, “China Environmental Monitoring, â€⋅ vol. 11, No. 4, pp. 7-9, Dec. 31, 1995.
Brynda, et al., The detection of toman 2-microglcbuiin by grating coupler immunosensor with three dimensional antibody networks. Biosensors & Bioelectronics, 1999, 363-368, 14(4).
Wheaton, et al., Dowex Ion Exchange Resins-Fundamentals of Ion Exchange; Jun. 2000, pp. 1-9. http://www.dow.com/scripts/litorder.asp?filepath=liquidseps/pdfs/noreg/177-01837.pdf.
Zhong, et. al., Miniature urea sensor based on H(+)-ion sensitive field effect transistor and its application in clinical analysis, Chin. J. Biotechnol., 1992, 57-65. 8(1).
PCT/US2012/034331, International Search Report and Written Opinion dated Jul. 9, 2012.
Roberts M, The regenerative dialysis (REDY) sorbent system. Nephrology, 1998, 275-278:4.
Hemametrics, Crit-Line Hematocrit Accuracy, 2003, 1-5, vol. 1, Tech Note No. 11 (Rev. D).
Weissman, S., et al., Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin. Infec. Dis, (Jul. 29, 1999): 223-224.
PCT/US2012/034334, International Search Report, Jul. 6, 2012.
PCT/US2012/034335, International Search Report, Sep. 5, 2012.
PCT/US/2012/034327, International Search Report, Aug. 13, 2013.
PCT/US/2012/034329, International Search Report, Dec. 3, 2012.
Foley, et al., Long Interdialytic Interval and Martality among Patients Receiving Hemodialysis, N Engl Jrnl Med. 2011:365(12):1099-1107.
PCT International Search Report from International Application No. PCT/US2014/067650, dated Mar. 9, 2015.
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-10G: Suppl.
PCT/US2014/067650 International Search Report Written Opinion mailed Mar. 9, 2015.
Bleyer, et al., Kidney International. Jun. 2006; 69(12):2268-2273.
Bleyer, et. al., Sudden and cardiac death rated in hemodialysis patients, Kidney International. 1999, 1553-1559: 55.
PCT/US2012/034335, International Preliminary Report on Patentability, Oct. 29, 2013.
PCT/US2012/034303, Internationa Search Report, Jul. 6, 2013.
PCT/US2012/034332, Internatonal Preliminary Report on Patentability, Oct. 29, 2013.
PCT/US2012/034333, International Preliminary Report on Patentability, Oct. 29, 2013.
PCT/US2012/034333, International Search Report, Aug. 29, 2012.
PCT/US2012/034327, International Preliminary Report on Patentability, Oct. 29, 2013.
PCT/US2012/034330, International Preliminary Report on Patentability, Oct. 29, 2013.
Culleton, BF et al. Effect of Frequent Nocturnal Hemodialysis vs. Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. 2007 Journal of the American Medical Association 298 (11), 1291-1299.
Redfield, et. al., Restoration of renal response to atria! natriuretic factor in experimental low-output heat failure, Am. J. Physiol., Oct. 1, 1989, R917-923:257.
Rogoza, et. al., Validation of A&D UA-767 device for the self-measurement of blood pressure, Blood Pressure Monitoring, 2000, 227-231, 5(4).
PCT/US2012/034329, International Preliminary Report on Patentability, Oct. 29, 2013.
Lima, et. al., An electrochemical sensor based on nanostructure hollandite-type manganese oxide for detection of potassium ion, Sensors, Aug. 24, 2009, 6613-8625, 9.
Maclean, et, al., Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat, J. App. Physiol., 1998, 1583-1592, 85(4).
U.S. Appl. No. 13/757,693, dated Feb. 1, 2013.
PCT/US2014/014357 International Search Report and Written Opinion dated May 19, 2014.
PCT/US2014/014357 International Search Report and Written Opinion mailed May 19, 2014.
Ronco et al. 2008, Cardiorenal Syndrome, Journal American College Cardiology, 52:1527-1539, Abstract.
Overgaard, et. al., Activity-induced recovery of excitability in K+-depressed rat soleus muscle, Am. J. P 280: R48-R55, Jan. 1, 2001.
Overgaard et. al., Relations between excitability and contractility in rate soleusmuscle: role of the NA+-K+ pump and NA+-K-S gradients. Journal of Physiology, 1999, 215-225, 518(1).
Zoccali, Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD, Clinical Epidemiology, J. Am Soc Nephrol 24:639-646, 2013.
Coast, et al. 1990, An approach to Cardiac Arrhythmia analysis Using Hidden Markov Models, IEEE Transactions On Biomedical Engineering. 1990, 37(9):826-835.
Weiner, et al., Article: Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease, Book: Primer on Kidney Diseases (Author: Greenberg, et al.), 2009,499-505, 5th Ed., Saunders Elsevier, Philadelphia, PA.
Velasco, Optimal Fluid Control can Normalize Cardiovascular Risk Markers and Limit Left Ventricular Hypertrophy in Thrice Weekly Dialysis Patients, Hemodialysis Intenational, 16:465-472, 2012.
Whitman, CKD and Sudden Cardiac Death: Epidemiology, Mechanisms, and Therapeutic Approaches, J Am Soc Nephrol, 23:1929-1939, 2012.
Hall, Hospitalization for Congestive Heart Failure: United States, 2000-2010, NCHS Data Brief, No. 108, Oct. 2012.
Albert, Fluid Management Strategies in Heart Failure, Critical Care Nurse, 32:20-32, 2012.
PCT/US2014/065201 International Search Report mailed May 26, 2015.
Genovesi, et al., Nephrology, Dialysis, Transplantation 2009; 24(8):2529-2536.
Secemsky, et. al., High prevalence of cardiac autonomic dysfunction and T-wave alternans in dialysis patients. Heart Rhythm, Apr. 2011, 592-598 : vol. 8, No. 4.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 1-140.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 141-280.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 281-420.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 421-534.
Wei, et. al., Fullerene-cryptand coated piezoelectric crystal urea sensor based on urease, Analytica Chimica Acta, 2001,77-85:437.
Leifer et al., A Study on the Temperature Variation of Rise Velocity for Large Clean Bubbles, J. Atmospheric & Oceanic Tech., vol. 17, pp. 1392-1402, Oct. 2000.
Talaia, Terminal Velocity of a Bubble Rise in a Liquid Column, World Acad. of Sci., Engineering & Tech., vol. 28, pp. 264-268, Published Jan. 1, 2007.
The FHN Trial Group. In-Center. Hemodialysis Six Times per Week versus Three Times per Week, New England Journal of Medicine, 2010 Abstract.
PCT/US2012/034332, International Search Report, Jul. 5, 2012.
Siegenthaler, et al., Pulmonary fluid status monitoring with intrathoracic impedance, Journal of Clinical Monitoring and Computing, 24:449-451, published Jan. 12, 2011.
John Wm Agar: Review: Understanding sorbent dialysis systems, Nephrology, vol. 15, No. 4, Jun. 1, 2010, pp. 406-411.
European Office Action in Application 12717020.7 dated Sep. 14, 2016.
Office Action in Chinese Application No. 201510511657.9 Dated Dec. 28, 2016.
Lakerveld et al, Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive behavior program aimed at lifestyle changes in people at risk: Design of a randomized controlled trial, 2008, BMC Endocrine Disorders, 8(6): 1-19.
Gordhandas et al, Real-Time Extraction and Analysis of Key Morphological Features in the Electrocardiogram, for Data Compression and Clinical Decision Support, 2004, Computational Physiology, pp. 15-18.
European Office Action in Application 12717020.7 dated Dec. 11, 2015.
PCT/US2012/034331 International Preliminary Report on Patentability and Written Opinion dated Oct. 29, 2013.
Office Action in Chinese Application No. 201280020932.1 Dated Jan. 7, 2015.
Office Action in Chinese Application No. 201280020932.1 Dated Apr. 3, 2015.
PCT/US2012/034330, International Search Report and Written Opinion dated Aug. 28, 2012.
Office Action in Chinese Application No. 201280020937.4 dated Mar. 22, 2016.
Office Action in Japanese Application No. 2014-508434 dated Nov. 16, 2015.
Office Action in Japanese Application No. 2014-508434 dated Dec. 8, 2014.
Office Action in Japanese Application No. 2014-508434 dated Nov. 4, 2016.
Office Action in European Application No. 12717019.9 dated Feb. 16, 2017.
Office Action in Chinese Application No. 201510511657.9 dated May 10, 2017.
PCT/US2014/065201 International Preliminary Report on Patentability mailed May 19, 2016.
Office Action in European Application No. EP 12717021.5 dated Feb. 3, 2017.
Office Action in Chinese Application No. 201510593695.3 dated Jul. 12, 2017.
Office Action in European Application No. EP 12719170.8 dated Jan. 14, 2015.
Office Action in Japanese Application No. JP 2014-508437 dated Dec. 8, 2014.
Nedelkov, et. al., Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry, Proteomics, 2002, 441-446, 2(4).
European Search Report App 14865374.4, Jun. 12, 2017.
European Search Report for Application No. 14865128.4 dated Jun. 20, 2017.
Green et al., Sudden Cardiac Death in Hemodialysis Patients: an In-Depth Review , Am J Kidney Dis 57(6)921:929; published Apr. 18, 2011.
Rajan et al. Generalized Feature Extraction for Time-Varying Autoregressive Models, IEEE Transacion Signal Processing vol. 44, No. 10; published Oct. 1, 1996.
AU Examiners Report for Application No. 2017246829, dated Jan. 9, 2021.
Australian Office Action for App. No. 2016349521, dated Aug. 31, 2020.
Castellanos, et al., Clinical Relevance of Intraperitoneal Pressure in Peritoneal Dialysis Patients, Perit Dial Int. Sep.-Oct. 2017;37(5):562-567. doi: 10.3747/pdi.2016.00267. Epub Jul. 11, 2017.
Chinese Office Action for App. No. 201710778666.3, dated Feb. 25, 2020.
Chinese Office Action for App. No. 201710778666.3, dated Jul. 15, 2020.
Chinese Office Action for App. No. 201710778666.3, dated Nov. 20, 2020.
Chinese Office Action for App. No. 201710779349.3, dated Jun. 1, 2020.
Chinese Office Action for App. No. 201710779964.4, dated Apr. 14, 2020.
Chinese Office Action for App. No. 201710779964.4, dated Aug. 26, 2020.
Chinese Office Action for App. No. 201780019237.6, dated Feb. 1, 2021.
Chinese Office Action for App. No. 201780019237.6, dated May 25, 2020.
Chinese Office Action for App. No. 201780019238.0, dated May 7, 2020.
Chinese Office Action for App. No. 201780019362.7, dated Jun. 2, 2020.
Chinese Office Action for App. No. 201810121459.5, dated Aug. 17, 2020.
Chinese Office Action for App. No. 201810121459.5, dated Mar. 19, 2020.
Chinese Office Action for App. No. 201811107614.4, dated Sep. 28, 2020.
Chinese Office Action for App. No. 201811155891.2, dated Oct. 10, 2020.
Chinese Office Action for App. No. 2019071601874110, dated Jul. 19, 2019.
Chinese Office Action in App. No. 201480059332.5, Dated Mar. 30, 2018.
Dejardin, et al, Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications, Nephrol Dial Transplant. May 2007;22(5):1437-44.
European Office Action for App. No. 12719842.2, dated Jul. 15, 2020.
European Office Action for App. No. 14859115.9, dated Mar. 25, 2020.
European Office Action for App. No. 17190053.3, dated Sep. 18, 2019.
European Office Action for App. No. 17718246.6, dated Apr. 2, 2020.
European Office Action for App. No. 18204841.3, dated Aug. 20, 2020.
European Office Action for App. No. 19173852.5, dated Aug. 28, 2020.
European Search For App. No. 17190081.4, dated Feb. 5, 2021.
European Search Report for App. No. 17185636.2, Dated Mar. 27, 2018.
European Search Report for App. No. 14859115.9, dated Jan. 5, 2018.
European Search Report for App. No. 17185636.2 dated Jan. 10, 2018.
European Search Report for App. No. 17185638.8, dated Dec. 19, 2017.
European Search Report for App. No. 17185808.7, dated Jan. 2, 2018.
European Search Report for App. No. 17185810.3, dated Dec. 15, 2017.
European Search Report for App. No. 17190053.3, dated Jan. 2, 2018.
European Search Report for App. No. 17190066.5, dated Jan. 16, 2018.
European Search Report for App. No. 17190081.4, dated Sep. 16, 2019.
European Search Report for App. No. 17190084.8, dated Feb. 9, 2018.
F. Locatelli, et al: “Haemodialysis with on-line monitoring equipment: tools or toys?” Nephrology Dialysis Transplantation., vol. 20, No. 1, Jan. 1, 2005.
Related Publications (1)
Number Date Country
20230036006 A1 Feb 2023 US